Targretin gel 1% — CareFirst (Caremark)
smoldering adult T-cell leukemia/lymphoma (ATLL)
Initial criteria
- Authorization may be granted for treatment of smoldering ATLL.
Reauthorization criteria
- Authorization may be granted if no evidence of unacceptable toxicity or disease progression while on current regimen.
Approval duration
12 months